Blood-based metabolic signatures may predict whether women with ovarian or uterine cancer will respond well to platinum-based chemotherapy, according to a study by researchers in the Department of Gynecology at the Federal University of São Paulo’s Medical School (EPM-UNIFESP) in … Read more
MEDICAL COLLEGE OF WISCONSIN
The study’s findings suggest targeting protein FXR1 to inhibit the progression of the cMYC oncogene, a gene mutation often over-expressed in patients with ovarian cancer
Scientists at the Medical College of Wisconsin (MCW) Cancer Center and … Read more
by Alison Kanski
NEW YORK – Pharma companies are racing to develop oral ATR inhibitors that present a unique pan-cancer market opportunity.
Researchers reported positive Phase I results on one of these drugs, Repare Therapeutics’ RP3500, last month across tumor … Read more
by Julie S. Brokaw
A woman with ovarian cancer describes how blood work numbers play a key role for patients with cancer and often dictate their thoughts and worries.
The number three is a special number. As a former math
RAD51C and RAD51D mutations and high-level BRCA1 promotor methylation are predictive of response to rucaparib in patients with recurrent ovarian cancer, while genomic scars linked with homologous recombination deficiency is predictive of response only in those with platinum-sensitive disease.
By … Read more
The study finally paves the way for the use of antibodies different from IgG as immunotherapeutic agents for at least tumors currently resistant to conventional immune checkpoint blockade.
The prognosis of ovarian cancer is poor, with an estimated five-year survival … Read more
By Angus Liu
Many oncology researchers and practitioners scrutinize genetic alterations in cancer, but they either focus on one particular tumor type or one mutation that occurs across tumors. A large-scale study focusing on precision medicine in cancer is now … Read more
Updated interim safety, tolerability, and efficacy data for the ovarian cancer cohort of the ongoing expansion portion of the Phase I study evaluating XMT-1536 show a 34% objective response rate (ORR) and 79% disease control rate, including two complete responses. … Read more
By Leah Lawrence
A new study estimated that a PARP inhibitor-for-all approach to treating advanced-stage ovarian cancer would be associated with high costs compared with biomarker-directed use of PARP inhibitors.1 Study researchers recommended that maintenance treatment with PARP inhibitors … Read more
In cell and mouse models, miR-181a showed promise as a biomarker for early stage ovarian cancer and may help make immunotherapy treatment more effective.
By Ian Demsky
A microRNA that is normally involved in immune cell differentiation helps to initiate
By Ian Ingram
For women with recurrent or persistent low-grade serous ovarian cancer (LGSOC), presence of a KRAS mutation appeared to predict benefit from binimetinib (Mektovi), a post-hoc analysis from the phase III MILO trial found.
Among women treated with … Read more
NEW YORK – The US Food and Drug Administration has approved olaparib (AstraZeneca/Merck’s Lynparza) in combination with bevacizumab (Genentech’s Avastin) as a maintenance regimen for advanced ovarian cancer patients who have homologous recombination deficiency (HRD) and are responding to first-line … Read more
by Marilynn Marchione
For the first time, a blood test has been shown to help detect many types of cancer in a study of thousands of people with no history or symptoms of the disease.
The test is still experimental. … Read more
By Jo Cavallo
The Circulating Cell-free Genome Atlas Study is a large multicenter, case-controlled, observational study of 15,254 participants, 56% with cancer and 44% without cancer, with longitudinal follow-up to support the development of a cell-free DNA (cfDNA) multicancer early … Read more
BOSTON–(BUSINESS WIRE)– Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced results from the ongoing investigator-initiated Phase 1 clinical study investigating VS-6766, its